1. Home
  2. FOLD vs BATRA Comparison

FOLD vs BATRA Comparison

Compare FOLD & BATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOLD
  • BATRA
  • Stock Information
  • Founded
  • FOLD 2002
  • BATRA 1991
  • Country
  • FOLD United States
  • BATRA United States
  • Employees
  • FOLD N/A
  • BATRA N/A
  • Industry
  • FOLD Biotechnology: Pharmaceutical Preparations
  • BATRA Broadcasting
  • Sector
  • FOLD Health Care
  • BATRA Industrials
  • Exchange
  • FOLD Nasdaq
  • BATRA Nasdaq
  • Market Cap
  • FOLD 2.9B
  • BATRA 2.6B
  • IPO Year
  • FOLD 2007
  • BATRA N/A
  • Fundamental
  • Price
  • FOLD $5.64
  • BATRA $49.07
  • Analyst Decision
  • FOLD Buy
  • BATRA Strong Buy
  • Analyst Count
  • FOLD 10
  • BATRA 2
  • Target Price
  • FOLD $16.22
  • BATRA $56.50
  • AVG Volume (30 Days)
  • FOLD 5.3M
  • BATRA 59.8K
  • Earning Date
  • FOLD 08-07-2025
  • BATRA 08-07-2025
  • Dividend Yield
  • FOLD N/A
  • BATRA N/A
  • EPS Growth
  • FOLD N/A
  • BATRA N/A
  • EPS
  • FOLD N/A
  • BATRA N/A
  • Revenue
  • FOLD $543,141,000.00
  • BATRA $672,879,000.00
  • Revenue This Year
  • FOLD $19.84
  • BATRA $8.81
  • Revenue Next Year
  • FOLD $23.18
  • BATRA $5.01
  • P/E Ratio
  • FOLD N/A
  • BATRA N/A
  • Revenue Growth
  • FOLD 28.25
  • BATRA 4.04
  • 52 Week Low
  • FOLD $5.62
  • BATRA $38.67
  • 52 Week High
  • FOLD $12.65
  • BATRA $49.47
  • Technical
  • Relative Strength Index (RSI)
  • FOLD 33.65
  • BATRA 79.66
  • Support Level
  • FOLD $6.00
  • BATRA $45.06
  • Resistance Level
  • FOLD $6.22
  • BATRA $45.82
  • Average True Range (ATR)
  • FOLD 0.19
  • BATRA 0.93
  • MACD
  • FOLD -0.01
  • BATRA 0.39
  • Stochastic Oscillator
  • FOLD 2.70
  • BATRA 93.99

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

About BATRA Atlanta Braves Holdings Inc. Series A

Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.

Share on Social Networks: